EEF1A2 and gastric cancer: The persistence of these epigenetic alterations from early intramucosal gastric cancers (IMCs) to advanced stages, as confirmed by The Cancer Genome Atlas (TCGA) data, positions eEF1A2 as a progression biomarker [28].